CLEAR Outcomes Company Update Call: Detailed Results Discussion
February 22 2023 - 8:00AM
Esperion (NASDAQ: ESPR) today announced it will host a conference
call and webcast on Monday, March 6th, 2023 where Esperion Chief
Medical Officer Dr. JoAnne Foody and CLEAR Outcomes Principal
Investigator Dr. Steven Nissen will discuss detailed results from
CLEAR Outcomes, which are being presented at the American College
of Cardiology Annual Scientific Session & Expo together with
the World Congress of Cardiology (ACC.23/WCC) on Saturday, March
4th, 2023.
The webcast and conference call will take place at 8:00 a.m. EST
/ 7:00 a.m. CST on March 6th, 2023. Please click here to
pre-register to participate in the conference call and obtain your
dial in number and PIN.
Already registered? Access with your PIN here.
A webcast of the live call will be available online in the
investor relations section of the Esperion website. Access to the
webcast replay will be available approximately two hours after
completion of the call and will be archived on the Company’s
website for approximately 90 days.
Esperion TherapeuticsAt Esperion, we discover,
develop, and commercialize innovative medicines to help improve
outcomes for patients with or at risk for cardiovascular and
cardiometabolic diseases. The status quo is not meeting the health
needs of millions of people with high cholesterol – that is why our
team of passionate industry leaders is breaking through the
barriers that prevent patients from reaching their goals. Providers
are moving toward reducing LDL-cholesterol levels as low as
possible, as soon as possible; we provide the next steps to help
get patients there. Because when it comes to high cholesterol,
getting to goal is not optional. It is our life’s work. For more
information, visit esperion.com and esperionscience.com and follow
us on Twitter at twitter.com/EsperionInc.
Contact:Esperion Corporate
Communicationscorporateteam@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Apr 2023 to Apr 2024